BioCentury
ARTICLE | Clinical News

Realm begins Phase II trial of PR022 for atopic dermatitis

December 8, 2017 7:04 PM UTC

Realm Therapeutics plc (LSE:RLM) started a Phase II trial of PR022 to treat adults with mild to moderate atopic dermatitis. Realm expects top-line data in 3Q18.

The double-blind, placebo-controlled, U.S. trial will evaluate twice-daily 0.05% and 0.1% topical PR022 for 28 days in about 120 patients with atopic dermatitis. The study's primary endpoint will measure the percent change in Eczema Area and Severity Index (EASI) from baseline to day 29...

BCIQ Company Profiles

Realm Therapeutics plc